Growing community of inventors

Berlin, Germany

Peter-Andreas Loschmann

Average Co-Inventor Count = 5.13

ph-index = 3

The patent ph-index is calculated by counting the number of publications for which an author has been cited by other authors at least that same number of times.

Forward Citations = 45

Peter-Andreas LoschmannHelmut Wachtel (5 patents)Peter-Andreas LoschmannGerhard Sauer (3 patents)Peter-Andreas LoschmannThomas Brumby (2 patents)Peter-Andreas LoschmannReinhard Horowski (2 patents)Peter-Andreas LoschmannJonathan Turner (2 patents)Peter-Andreas LoschmannHerbert H Schneider (1 patent)Peter-Andreas LoschmannPaul-Eberhard Schulze (1 patent)Peter-Andreas LoschmannHermann Graf (1 patent)Peter-Andreas LoschmannRainer Dorow (1 patent)Peter-Andreas LoschmannBernard Acksteiner (1 patent)Peter-Andreas LoschmannH Daniel Perez (1 patent)Peter-Andreas LoschmannWalther Birkmayer (1 patent)Peter-Andreas LoschmannJorg Birkmayer (1 patent)Peter-Andreas LoschmannPeter-Andreas Loschmann (5 patents)Helmut WachtelHelmut Wachtel (42 patents)Gerhard SauerGerhard Sauer (58 patents)Thomas BrumbyThomas Brumby (21 patents)Reinhard HorowskiReinhard Horowski (13 patents)Jonathan TurnerJonathan Turner (8 patents)Herbert H SchneiderHerbert H Schneider (36 patents)Paul-Eberhard SchulzePaul-Eberhard Schulze (9 patents)Hermann GrafHermann Graf (5 patents)Rainer DorowRainer Dorow (4 patents)Bernard AcksteinerBernard Acksteiner (4 patents)H Daniel PerezH Daniel Perez (2 patents)Walther BirkmayerWalther Birkmayer (1 patent)Jorg BirkmayerJorg Birkmayer (1 patent)
..
Inventor’s number of patents
..
Strength of working relationships

Company Filing History:

1. Schering Aktiengesellschaft (5 from 1,384 patents)


5 patents:

1. 6060501 - Combined treatment of multiple sclerosis

2. 5547958 - N-(8.alpha.-ergolinyl)-amides

3. 5212178 - 8.alpha.-acylamino ergolines and use as pharmaceutical agents

4. 4970200 - Agent for treatment of Parkinson's disease

5. 4857298 - I*-diagnostics for monoamine receptors using ergolines

Please report any incorrect information to support@idiyas.com
idiyas.com
as of
1/2/2026
Loading…